The lack of significant differences in ccf mtDNA/Il-6 levels between unaffected heterozygous mutation carriers and healthy control subjects or patients with sporadic Parkinson’s disease suggests that even slight parkin/PINK1 level/activity deregulation may be determinant in the transition from health to disease state. This evidence concerns the gene PRKN and Parkinson disease.